Share on StockTwits

Cellular Biomedicine Group (NASDAQ:CBMG) Director David Bolocan bought 10,000 shares of the company’s stock on the open market in a transaction dated Thursday, June 26th. The stock was purchased at an average price of $5.00 per share, with a total value of $50,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $50,000. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Shares of Cellular Biomedicine Group (NASDAQ:CBMG) traded up 1.59% during mid-day trading on Friday, hitting $14.5001. The stock had a trading volume of 4,392 shares. Cellular Biomedicine Group has a 1-year low of $4.51 and a 1-year high of $15.98. The stock’s 50-day moving average is $10. and its 200-day moving average is $8.60. The company’s market cap is $109.9 million.

Cellular Biomedicine Group, Inc develops cell therapies for the treatment of certain degenerative diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.